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Abstract
von Willebrand factor (VWF) is essential for normal hemostasis. VWF gene mutations cause the hemorrhagic von Willebrand
disease (VWD). In this study, a 9-year-old boy was diagnosed as type 2A VWD, based on a history of abnormal bleeding, low
plasma VWF antigen and activity, low plasma factor VIII activity, and lack of plasma high-molecular-weight (HMW) VWF
multimers. Sequencing analysis detected a 6-bp deletion in exon 28 of his VWF gene, which created a mutant lacking
D1529V1530 residues in VWF A2 domain. This mutation also existed in his family members with abnormal bleedings but not
in .60 normal controls. In transfected HEK293 cells, recombinant VWF DD1529V1530 protein had markedly reduced levels
in the conditioned medium (4264% of wild-type (WT) VWF, p,0.01). The mutant VWF in the medium had less HMW
multimers. In contrast, the intracellular levels of the mutant VWF in the transfected cells were significantly higher than that
of WT (174629%, p,0.05), indicating intracellular retention of the mutant VWF. In co-transfection experiments, the mutant
reduced WT VWF secretion from the cells. By immunofluorescence staining, the retention of the mutant VWF was identified
within the endoplasmic reticulum (ER). Together, we identified a unique VWF mutation responsible for the bleeding
phenotype in a patient family with type 2A VWD. The mutation impaired VWF trafficking through the ER, thereby
preventing VWF secretion from the cells. Our results illustrate the diversity of VWF gene mutations, which contributes to the
wide spectrum of VWD.
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Introduction
von Willebrand factor (VWF) is a multimeric glycoprotein that
plays an important role in hemostasis [1,2]. VWF mediates platelet
adhesion at damaged vascular sites and protects plasma factor
VIII (FVIII) from proteolytic degradation. In vascular endothelial
cells and megakaryocytes, VWF is synthesized as a 2813-amino
acid processor consisting of multiple domains in the order of D1-
D2-D9-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK. After removal of
the signal peptide, VWF monomers in the endoplasmic reticulum
(ER) form dimers by connecting their C-termini through disulfide
bonds. VWF dimers then translocate to the Golgi to form high-
molecular-weight (HMW) multimers by linking cysteine residues at
their N-termini. The assembled VWF is either constitutively
secreted or stored in Weibel-Palade bodies of endothelial cells or
a-granules of platelets. The HMW multimers are critical for VWF
to mediate platelet adhesion under high shear flow conditions
[1,2].
von Willebrand disease (VWD) is the most common inherited
bleeding disorder caused by mutations in the VWF gene
[3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18], which result in quan-
titative and/or qualitative defects in VWF [2,19]. VWD is
classified into three types: types 1 and 3 refer to different degrees
of quantitative VWF deficiencies, whereas type 2 refers to all
qualitative VWF deficiencies. Type 2 VWD is subdivided into
types 2A, 2B, 2M, and 2N. Type 2A refers to qualitative variants
with decreased platelet adhesion activity and a selective loss of
HMW VWF multimers [19]. Identification of VWF gene
mutations in VWD subtypes has helped to understand the
molecular basis underlying VWD and the structure-function
relationship of VWF.
In this study, we diagnosed a patient family with type 2A VWD.
DNA sequence analysis of the VWF gene in the patients identified
a novel 6-base pair (bp) deletion in exon 28, which encodes the C-
terminal half of VWF A2 domain. In functional studies, the
mutation did not prevent VWF expression in transfected human
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33263embryonic kidney (HEK)293 cells but markedly impaired VWF
secretion from the cells. The results help to explain the findings of
low plasma VWF levels but normal platelet VWF levels in the
patients and support the importance of A2 domain in VWF
biosynthesis and secretion.
Results
Diagnosis of a patient family with type 2A VWD
The proband was a 9-year-old boy, whose family pedigree is
shown in Fig. 1. He suffered from frequent bruise, epistaxis,
prolonged bleedings from small wounds, and delayed wound
healing. His mother also had a history of epistaxis, menorrhagia
and anemia. His father did not experience any abnormal
bleedings. Several members in the extended family had bleeding
tendencies. The results of laboratory tests from the proband and
some of his family members are shown in Table 1, which indicated
normal clotting times but low plasma VWF antigen and activity in
the proband (V-2), and the family members III-3, IV-2, IV-3 and
IV-4.
We analyzed VWF multimers in plasma and platelets from
these individuals. Plasma VWF from the proband, III-3, IV-2, IV-
3 and IV-4 lacked high or intermediate MW multimers, whereas
VWF from the proband’s father (IV-5) had a similar multimer
pattern to that of a normal control (Fig. 2A). In contrast, platelet
VWF from these individuals all had HMW multimers that were
indistinguishable from those of normal controls (Fig. 2B). Based on
these data and the results of laboratory tests, including low plasma
VWF Ag and activities (Table 1), the proband and 4 additional
family members (III-3, IV-2, IV-3 and IV-4) were diagnosed for
type 2A VWD.
Identification of a VWF gene mutation
To understand the genetic basis underlying the VWD in this
family, we isolated genomic DNA from the proband and
sequenced all 52 exons in his VWF gene. We found overlapping
peaks in the sequencing chromatogram of exon 28 (data not
shown), suggesting a heterozygous mutation. To verify this VWF
gene mutation, we separated DNA fragments from the patient’s
two alleles by PCR amplification and cloning of the DNA
fragments into pMD18-T vector. Sequencing analysis of the
resulting plasmids showed that the patient had one normal VWF
allele and a mutant allele with a 6-bp deletion in exon 28, which
encoded amino acids D1529 and V1530 in VWF A2 domain
(Fig. 3). The deletion kept the remaining coding sequence in-
frame. We did not find any additional insertion, deletion or non-
synonymous point mutations in his VWF gene. This 6-bp deletion
mutation also existed in his mother (IV-4) and three other family
members (III-3, IV-2 and IV-3) with bleeding symptoms but not in
his father (IV-5) and more than 60 unrelated normal controls,
indicating that this mutation is responsible for the VWD in this
family.
Analysis of recombinant mutant VWF
We constructed a plasmid expressing mutant VWF with
D1529V1530 deletion (DD1529V1530) and transfected the
plasmid into HEK293 cells. Recombinant VWF in the condition
medium and cell lysates was quantified by ELISA (Table 2).
Compared with control recombinant wild-type (WT) VWF in
similarly transfected cells, VWF DD1529V1530 mutant had a
higher intracellular level (174629%, p,0.05). The level of the
mutant VWF in the conditioned medium, however, was markedly
reduced compared to that of WT control (4264%, p,0.01).
To test the hypothesis that the mutant VWF allele may interfere
with the expression of the normal VWF allele in the patients, we
mixed equal amounts of plasmids for WT and DD1529V1530
mutant VWF and transfected them into HEK293 cells. ELISA
analysis of cell lysates showed higher levels of recombinant VWF
expression in HEK293 cells transfected with both WT and
DD1529V1530 mutant plasmids (Table 2). The levels in the
conditioned medium from these cells, however, were significantly
lower than that from the cells transfected with WT plasmid alone
(61616% of WT, p,0.05). The reduced levels were similar to that
from the cells transfected with one-half amount of WT plasmid
(Table 2). The results indicate that DD1529V1530 mutant
impaired WT VWF secretion from the transfected cells.
We then analyzed the multimer pattern of recombinant WT
and mutant VWF from the transfected cells. As shown in Fig. 4,
recombinant WT VWF from the conditioned medium had HMW
multimers. In contrast, VWF DD1529V1530 mutant from
similarly transfected cells had lower expression levels and less
HMW multimers. In the conditioned media from the cells
transfected with both the mutant and WT plasmids or one-half
amount of WT plasmid alone, VWF protein expression levels were
lower but HMW multimers were clearly present (Fig. 4).
Figure 1. Pedigree of the family with bleeding disorder. Squares
and circles indicate males and females, respectively, and arrow indicates
the proband. Black color denotes affected individuals. A slash through
the symbol indicates decreased individuals.
doi:10.1371/journal.pone.0033263.g001
Table 1. Main laboratory findings of the patient and family
members.
V-2 III-3 IV-2 IV-3 IV-4 IV-5
Normal
Range
TT, sec 16.7 16.7 15.6 18.6 18.1 17.1 14–21
APTT, sec 58.1 45.5 45.8 45.2 46.1 36.6 28–40
PT, sec 14.2 14.0 13.8 13.4 14.1 13.0 11–14.5
RIPA, % 28.5 N/A N/A N/A 3.0 85.0 50–150
VWF:Ag, U/dL 20.5 21.6 30.4 19.5 21.7 95.2 50–150
VWF:Rco, U/dL 6.2 5.0 8.4 7.6 5.0 94.5 50–150
FVIII:C, U/dL 25.0 28.0 50.0 29.0 N/A 79.0 50–150
TT, thrombin time; APTT, activated partial thromboplastin time; PT,
prothrombin time; RIPA, ristocetin-induced platelet agglutination; VWF:Ag, VWF
antigen; VWF:RCo, VWF ristocetin cofactor activity; FVIII:C, FVIII coagulant
activity; N/A, not available.
doi:10.1371/journal.pone.0033263.t001
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mutant VWF proteins inside the cells by co-staining with protein
disulfide isomerase (PDI), an ER protein marker. As shown in
Fig. 5 (middle row panels), recombinant WT VWF was detected in
transfected HEK293 cells. The protein was present around the
nucleus and in the cytoplasm where the staining was granule-like.
There were limited overlaps between VWF and PDI expression.
In similarly transfected HEK293 cells, the mutant VWF was
detected mostly around the nucleus and the expression pattern
overlapped with that of PDI (Fig. 5, lower panels). The results
indicate that a significant portion of the mutant VWF molecules
was retained in the ER in these cells.
Discussion
In this study, we report a patient family with type 2A VWD.
The diagnosis was based on the VWD classification [9,19], which
includes a history of moderate bleeding, low levels of plasma
VWF:Ag, reduced VWF:CB and VWF:Rco activities, decreased
FVIII coagulant activity, and lack of high and intermediate MW
VWF multimers. Sequencing analysis of the VWF gene exons of
the proband identified a 6-bp deletion in exon 28. This mutation
has never been reported in the literature and is predicted to create
a mutant VWF that lacks residues D1529V1530 in A2 domain.
This novel mutation was found in 4 additional family members,
who had similar clinical symptoms and laboratory findings, but
not in .60 normal controls.
We expressed and characterized VWF DD1529V1530 mutant
in transfected HEK293 cells. Unlike the previously reported
delR1569 mutation in VWF A2 domain, which greatly reduced
VWF expression [20], the deletion of D1529V1530 did not
prevent VWF expression in HEK293 cells, as indicated by higher
levels of VWF protein in cell lysate (Table 2). The secretion of this
mutant from the cells, however, was markedly impaired, as
indicated by low levels of mutant VWF in the conditioned medium
(Table 2). The mutant also decreased the levels of recombinant
WT VWF in the conditioned medium when they were co-
expressed, exhibiting a dominant-negative effect on VWF
secretion (Table 2). These data were consistent with the findings
of low plasma VWF levels but normal platelet VWF levels in these
patients. Similar findings of normal cellular expression but
reduced secretion were reported in other type 2A VWD patients
who had mutations in VWF A2 [20,21], D3 or CK domains [22].
The dominant-negative effect of DD1529V1530 mutant on WT
VWF secretion in transfected cells may also explain the autosomal
dominant inheritance observed in this patient family.
In patients with type 2A VWD, mutations in VWF A1 and A2
domains often resulted in the loss of HMW, and sometimes
intermediate MW, multimers [7,23]. It is proposed that type 2A
VWD may be divided into groups I and II, based on different
molecular defects [7,11,21,24]. In group I, mutations impair the
intracellular transport, storage or secretion of VWF, especially
HMW multimers. The reported VWF mutations that belong to
this group include L1503R [11], G1505R, S1506L [21], L1540P
Figure 2. Analysis of plasma and platelet VWF multimers. Plasma (A) and platelet (B) VWF multimers were assessed by 1.6% SDS-agarose gel
electrophoresis and Western blotting. Normal plasma samples were diluted 1:20 and patient plasma samples were diluted 1:5. Samples from family
members and a normal control (N) were indicated. Platelet samples were not available from IV-4.
doi:10.1371/journal.pone.0033263.g002
Figure 3. Identification of a VWF gene mutation. Sequence
analysis of the VWF gene in the proband detected a 6-bp nucleotides
deletion in exon 28. The mutation caused D1529V1530 deletion
(DD1529V1530) in VWF A2 domain. The ADAMTS13 cleavage site is
indicated by an arrow.
doi:10.1371/journal.pone.0033263.g003
Table 2. Expression of WT and mutant VWF in transfected
HEK293 cells.
Plasmid Cell Lysate Conditioned Medium
VWF:Ag (%) VWF:Ag (%)
VWF:CB
(%) VWF:CB/VWF:Ag
WT 100628 100612 100612 1.0
Mutant 174629* 4264** 1664** 0.38
Mutant/WT 121652 61616* 21616** 0.34
WT (1/2) 58621 6867* 3267** 0.47
VWF:Ag, VWF antigen; VWF:CB, VWF collagen-binding activity; WT, wild-type
VWF; WT (1/2), one-half amount of WT plasmid; Data represent mean 6 SD,
**p,0.01 vs. WT,
*p,0.05 vs. WT. Data were from three independent experiments.
doi:10.1371/journal.pone.0033263.t002
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VWF protein synthesis, intracellular transport or secretion, but
render the protein more susceptible to ADAMTS13, which cleaves
VWF at Y1605-M1606 in A2 domain [7,24,26] (Fig. 3). These
data indicate that mutations in A2 domain, depending on their
specific positions and the nature of amino acid changes, may have
different effects on the intracellular trafficking and posttransla-
tional degradation of VWF.
Unlike most point mutations reported in type 2A VWD that
alter single amino acids, the mutation we found in this study
deleted two amino acids in A2 domain while the remaining VWF
sequence was kept in-frame. Mechanistically, the type 2A VWD
caused by this deletion mutation belongs to group I because the
mutation impaired VWF secretion. As shown by ELISA and
multimer analysis (Table 2 and Fig. 4), mutant VWF in the
conditioned medium was at low levels and had less HMW
multimers, consistent with low levels of plasma VWF that also
lacked HMW mulitmers in these patients (Fig. 2A). We showed
that co-expression of WT VWF did not significantly improve the
secretion of the mutant in transfected cells (Table 2). In this regard,
this mutant VWF differed from some of quantitative VWF
mutants in D3 and CK domains, which also had reduced secretion
in transfected HEK293 cells. The defective secretion of these
quantitative VWF mutants, however, was attenuated if WT VWF
was co-expressed, resulting in normal amounts of HMW multi-
mers in the conditioned medium [27,28]. These data indicate that
DD1529V1530 mutant may interact with WT VWF and impair
the intracellular trafficking and secretion of WT VWF. In the
patients, however, it is unlikely that the mutation completely
blocked the VWF intracellular trafficking since HMW VWF
multimers were detected in the patients’ platelets (Fig. 2A). The
data suggest that DD1529V1530 mutation may impair both the
intracellular trafficking and secretion of VWF in the patients.
In summary, we identified a novel deletion mutation in VWF
A2 domain in a family of patients with type 2A VWD. In
functional studies, we showed that the mutation did not prevent
VWF expression but markedly impaired VWF secretion in
Figure 4. Multimer analysis of recombinant VWF expressed in
HEK293 cells. Multimeric analysis of recombinant VWF was performed
with the conditioned medium from HEK293 cells transfected with
plasmids for WT and the mutant, individually or in combination. Samples
from the vector-transfected cells were used as a negative control.
doi:10.1371/journal.pone.0033263.g004
Figure 5. Detection of WT and mutant VWF in transfected HEK293 cells by immunostaining. HEK293 cells were transfected with a control
vector or plasmids expressing WT or mutant VWF. The cells were stained for VWF (red), PDI (green) or DAPI (nucleus, blue). In the right column panels,
merged pictures of green, red and blue channels are shown. The images were obtained with a confocal microscope. Scale bars: 10 mm.
doi:10.1371/journal.pone.0033263.g005
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genetic basis of the bleeding phenotype in this patient family and
provide new data to illustrate the diversity of VWF gene mutations
that contributes to the wide spectrum of VWD.
Materials and Methods
Blood samples and laboratory tests
This study was approved by the Ethics Committees of the First
Affiliated Hospital of Soochow University and all participants gave
informed consent. Blood was collected in tubes containing 3.2% of
sodium citrate [1:10 (v/v)] as an anticoagulant. Plasma was
prepared by centrifugation of blood samples at 12, 0006 g for
5 min, aliquoted and stored at 280uC until use. Platelet-rich
plasma (PRP) and platelet-poor plasma (PPP) were prepared by
centrifugation of blood samples at 1006g for 10 min and 8006g
for 15 min, respectively.
VWF antigen (VWF:Ag) and VWF ristocetin cofactor activity
(VWF:Rco) were measured by ELISA [29]. VWF collagen-
binding activity (VWF:CB) was measured using an ELISA-based
assay with human type III collagen (Sigma, St Louis, MO, USA)
[30]. Ristocetin-induced platelet aggregation (RIPA) was done on
a platelet aggregometer (Chronolog) in the presence of 1.25 mg/
mL ristocetin (Sigma). Plasma FVIII activity was measured by a
one-stage method [31].
VWF multimer analysis
Analysis of VWF multimers in plasma and platelets from
patients or in the conditioned medium from transfected cells
expressing recombinant VWF was performed using 1.6% SDS-
agarose gel electrophoresis, as previously described [10,32]. VWF
multimers in the gel were transferred to a nitrocellulose membrane
and detected by an HRP-conjugated rabbit anti-human VWF
antibody (Dako, Glostrup, Denmark).
DNA extraction and sequencing
Genomic DNA was extracted from peripheral blood leukocytes
using the QIAamp Blood Kit (Qiagen), according to the
manufacturer’s instruction. DNA sequences from all 52 exons
and intron–exon boundaries of the VWF gene were amplified by
PCR using oligonucleotide primers that were listed publicly
http://www.euvwd.group.shef.ac.uk/sequence.htm. PCR prod-
ucts were sequenced directly by a DNA analyzer (Applied
Biosystems 310). To verify possible heterozygous deletions or
insertions in patients, amplified DNA fragments with candidate
mutations were cloned into pMD18-T vector (Takara), and inserts
from the resulting plasmids were sequenced. The new sequence
data has been deposited in GenBank (accession number:
BankIt1476860 Seq1 JN625247).
Plasmid construction
The plasmid pSVHVWF containing the full-length human
VWF cDNA was kindly provided by Evan Sadler (Washington
University School of Medicine, St Louis, USA) [33]. A PCR-based
method was used to construct expression vectors encoding VWF
mutants using the full-length human VWF cDNA as a template.
Oligonucleotide primers 59-tga ttc agc gga tgg gcc agg aca gc-39
and 59-gct gtc ctg gcc cat ccg ctg aat ca -39 were used to make the
plasmid expressing the mutant VWF with D1529V1530 deletion
(DD1529V1530). In this study, the amino acid numbering was
based on human pro-VWF. The entire cDNA insert for the
mutant VWF in the expression vector was verified by sequencing.
Expression of recombinant VWF
HEK293 cells [34] were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum at 37uC in an incubator with 5% CO2. Transient
transfection was performed using LipofectAMINE 2000 (Invitro-
gen), as described previously [35]. The conditioned medium was
collected 48 h after transfection and centrifuged at 15,000 rpm to
remove cell debris. The cells were lysed in a buffer containing
100 mM Tris-HCl, pH 7.5, and 1% Triton X-100. Recombinant
VWF in the conditioned medium and cell lysates was quantified by
ELISA and analyzed for its multimeric structure.
Confocal immunofluorescence microscopy
For immunofluorescence staining of recombinant VWF in cells
[16], HEK293 cells were cultured on coverslips in 6-well plates
and transfected with VWF expressing plasmids. After 48 h, the
cells were fixed with 4% paraformaldehyde, permeabilized in 1%
Triton X-100 and blocked with 5% bovine serum albumin in
phosphate-buffered saline. Cells were incubated with first
antibodies and then with fluorescence-conjugated secondary
antibodies. A polyclonal anti-VWF antibody (Dako) and a
monoclonal anti-human PDI antibody (BD Bioscience) were used
to visualize VWF and the ER, respectively. Alexa 488- and Alexa
594-conjugated secondary antibodies were from Invitrogen.
Fluorescent images were acquired with a confocal microscope
(NIKON TE2000-E).
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